Illumina, Inc. (ETR:ILU)

Germany flag Germany · Delayed Price · Currency is EUR
77.31
-1.08 (-1.38%)
Jun 11, 2025, 5:35 PM CET
Market Cap 12.20B
Revenue (ttm) 4.00B
Net Income (ttm) -891.81M
Shares Out n/a
EPS (ttm) -5.61
PE Ratio n/a
Forward PE 20.52
Dividend 2.89 (3.80%)
Ex-Dividend Date Jun 25, 2024
Volume 165
Average Volume 228
Open 77.05
Previous Close 78.39
Day's Range 77.02 - 78.27
52-Week Range 62.00 - 150.56
Beta 1.13
RSI 61.72
Earnings Date Aug 7, 2025

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]

Sector Healthcare
Founded 1998
Employees 9,030
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ILU
Full Company Profile

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD Financial Statements

News

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina ...

13 days ago - PRNewsWire

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

14 days ago - CNBC Television

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illum...

14 days ago - PRNewsWire

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel

FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, an...

23 days ago - Business Wire

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

Carl Icahn is making bold moves from the lab to the tarmac.

26 days ago - Benzinga

Quantum-Si (QSI) Earnings Coverage: Complete 1Q Coverage

Live Updates Live Coverage Updates appear automatically as they are published. QSI Earnings Backdrop 11:26 am Quantum-Si operates at the intersection of biotech instrumentation and proteomics, targeti...

27 days ago - 24/7 Wall street

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi...

4 weeks ago - PRNewsWire

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, ...

4 weeks ago - PRNewsWire

Illumina Analysts Lower Their Forecasts After Q1 Results

Illumina, Inc. (NASDAQ: ILMN) reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday. The company posted quarterly earnings of 97 cents per ...

4 weeks ago - Benzinga

Illumina Analysts Lower Their Forecasts After Q1 Results

Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.

4 weeks ago - Benzinga

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac...

5 weeks ago - PRNewsWire

Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know

April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ: ILMN), valued between $3,003 and $45,000. According to the April filing, the transaction occurred...

7 weeks ago - Benzinga

Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.

7 weeks ago - GlobeNewsWire

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN...

2 months ago - PRNewsWire

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025.  O...

2 months ago - PRNewsWire

Snowflake Unveils Apache Iceberg™ Innovations, Giving Enterprises the Best of Open Data and AI-Ready Performance

Customers now get the best of both worlds: Iceberg’s flexibility and interoperability coupled with Snowflake’s powerful platform to make their data easy, connected, and trusted Thousands of customers ...

2 months ago - Financial Post

Apple To $250? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Citigroup...

2 months ago - Benzinga

Corvexs Meister joins the board at Illumina. Heres how he can create value for shareholders

Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.

2 months ago - CNBC